ALK-B.CO
BuyFallen FavouriteALK-Abelló A/S · Healthcare · Denmark · $6.7B
DKK 202.40 +0.4% · close 5 Oct · scored 7 Oct
Fallen Favourite: A good business, still expensive, and the price is falling.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT ALK-ABELLÓ A/S
Read
ALK-Abelló A/S is a global research-driven pharmaceutical company specializing in allergy immunotherapy, designed to treat the underlying cause of allergic diseases. The company is the undisputed market leader in sublingual allergy immunotherapy (SLIT) tablets, offering a comprehensive portfolio targeting grass, tree, ragweed, and house dust mite allergies. ALK's competitive moat is sustained by its complex biological manufacturing processes, extensive clinical trial data, and global regulatory approvals.
FINANCIAL SUMMARY (DKK)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.5B | 4.8B | 5.5B | 6.3B | 11.8% | 6.9B | 7.3B | 8.2B | 13.9% |
| EPS (DKK) | 1.52 | 2.20 | 3.68 | 5.40 | 52.6% | 6.14 | 6.51 | 7.23 | 15.7% |
| Shares | 221.0M | 221.2M | 221.4M | 221.6M | +0.3% | 201.6M | — | — | — |
| Debt | 696.0M | 765.0M | 1.2B | 418.0M | -15.6% | 424.3M | — | — | — |
| Equity | 4.0B | 4.4B | 5.4B | 6.4B | 17.4% | — | — | — | — |
| Op CF | 416.0M | 667.0M | 1.2B | 1.8B | 63.5% | 2.2B | — | — | — |
| Inv CF | -351.0M | -375.0M | -1.4B | -385.0M | — | — | — | — | — |
| Fin CF | -42.0M | -31.0M | 310.0M | -760.0M | — | — | — | — | — |
Calmer than 78% of stocks we rank over the past year (27% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALK-B.CO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALK-B.CO | ALK-Abelló A/S(you) | $6.7B | 72 | Buy |
| GMAB.CO | Genmab A/S | $21.5B | 75 | Buy |
| ZEAL.CO | Zealand Pharma A/S | $2.8B | 83 | Strong Buy |
| ASND | Ascendis Pharma A/S | $14.7B | 58 | Hold |
| BAVA.CO | Bavarian Nordic A/S | $2.5B | 98 | Strong Buy |
| GUBRA.CO | Gubra A/S | $764M | 33 | Sell |
| SANION.ST | Saniona AB (publ) | $138M | 81 | Strong Buy |
| CBHD.DE | Coloplast A/S | $14.3B | 73 | Buy |
| DEMANT.CO | Demant A/S | $10.0B | 82 | Strong Buy |
| GN.CO | GN Store Nord A/S | $2.4B | 74 | Buy |
Peer medians: ROE 15.9% · P/E 14.6x · Gross margin 82.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.